That recent seekingalpha article is up to 245 comm
Post# of 155125
(Total Views: 166)
Posted On: 03/01/2019 6:10:47 AM
That recent seekingalpha article is up to 245 comments if you have not read them, the most I have seen, and still going some. Here is a good one from last night
https://seekingalpha.com/article/4243443-cytodyn-good-true
Congrats OOI,
This is just about the most comments I have witnessed for an article covering a poetntial HIV meds company! I certainly hope you are getting something back from SA for the click count?
I am NOT giving up on the possibility of GILD acquiring CYDY.
1. Plenty of manufacturing outsourcing experience, expertise, and contacs, especially in India and China.
2. Milestone payments (seen it, done it, great at it) with the most recent example of
filgotibin with Galapagos.
4. Perfect fit for Pro 140 combo with any/most of the establshed HIV meds.
5. Heck if that works for breast cancer,m then a huge opportunity to go beyond th current rather limited CAR-T compounds.
6. Can Pro140 repeat the path of Keytruda with huge potential for expanded oncology idications?
6. Could Pro 140 finally fulfill the Holy Grail of "anchoring" compound (Tenoobir/TAF for HIV meds and sofosbucir for HCV meds)?
7. What better way to make use of rathe than sitting on all the pile of cash?
8. What better way to finally be able to brake out and rasie the SP to close to if not go above $100?
9. What better move by the new CEO to declare to the investmentc ommuity that the days of JCM (John C Martin) and JM (John Milligan) doldrums are finally over and done with and that he has how own bold vision, perspective, strategy, and business acumen unlike his obsolete and out of touch and conservative predecessors.
Your thoughts?
https://seekingalpha.com/article/4243443-cytodyn-good-true
Congrats OOI,
This is just about the most comments I have witnessed for an article covering a poetntial HIV meds company! I certainly hope you are getting something back from SA for the click count?
I am NOT giving up on the possibility of GILD acquiring CYDY.
1. Plenty of manufacturing outsourcing experience, expertise, and contacs, especially in India and China.
2. Milestone payments (seen it, done it, great at it) with the most recent example of
filgotibin with Galapagos.
4. Perfect fit for Pro 140 combo with any/most of the establshed HIV meds.
5. Heck if that works for breast cancer,m then a huge opportunity to go beyond th current rather limited CAR-T compounds.
6. Can Pro140 repeat the path of Keytruda with huge potential for expanded oncology idications?
6. Could Pro 140 finally fulfill the Holy Grail of "anchoring" compound (Tenoobir/TAF for HIV meds and sofosbucir for HCV meds)?
7. What better way to make use of rathe than sitting on all the pile of cash?
8. What better way to finally be able to brake out and rasie the SP to close to if not go above $100?
9. What better move by the new CEO to declare to the investmentc ommuity that the days of JCM (John C Martin) and JM (John Milligan) doldrums are finally over and done with and that he has how own bold vision, perspective, strategy, and business acumen unlike his obsolete and out of touch and conservative predecessors.
Your thoughts?
(0)
(0)